Platelet Rich Plasma Market by Source Type, Application

Description

List of Tables

[180 Pages Report] The Platelet Rich Plasma Market size was estimated at USD 381.63 million in 2023 and expected to reach USD 430.86 million in 2024, at a CAGR 12.09% to reach USD 848.54 million by 2030.

Platelet-rich plasma, referred to as PRP, is a concentrated form of plasma derived from whole blood rich in platelets. PRP is prepared by centrifuging a sample of the patient's blood, resulting in a platelet concentration above baseline values. The therapeutic use of PRP has gained popularity due to its potential to augment the body's innate healing process. PRP can be applied in various medical fields, including orthopedics, dentistry, sports medicine, wound healing, and the burgeoning field of aesthetic medicine. Increasing demand for minimally invasive treatments, a rise in the prevalence of sports injuries and orthopedic conditions, and an aging population seeking cosmetic and anti-aging treatments have proliferated the need for platelet rich plasma products and treatments. However, the need for more high-quality, randomized controlled trials to prove its efficacy for various indications and the high cost of PRP therapy can limit patient access to platelet rich plasma products and treatments. Nevertheless, the ongoing technological innovations to improve PRP treatments' efficacy, safety, and convenience are expected to contribute to adopting PRP treatments. Moreover, collaborative efforts with academic institutions to produce the robust clinical data necessary to validate applications encourage the adoption of PRP treatments in the coming years.

KEY MARKET STATISTICS
Base Year [2023]	USD 381.63 million
Estimated Year [2024]	USD 430.86 million
Forecast Year [2030]	USD 848.54 million
CAGR (%)	12.09%

Source Type: Preference for Autologous PRP due to its safety profile

Allogenic PRP refers to platelet-rich plasma harvested from a donor rather than the treated patient. Allogenic PRP is often used in cases where the patient is unable to provide a sufficient quantity of platelets or is at risk of adverse reactions from autologous PRP. Allogenic PRP needs to undergo rigorous testing to screen for pathogens and ensure compatibility with the recipient. Regarding preferences, allogenic PRP is specified when autologous PRP is not an option or when there's a risk of disease transmission. Autologous PRP is derived from the patient's blood, significantly reducing the risk of immunogenic reactions or disease transmission. This is the most common form of PRP due to its safety profile. Autologous PRP is typically preferred for patients who require PRP treatments for orthopedic injuries and cosmetic procedures. Homologous PRP refers to platelet-rich plasma that is used differently than its natural function within the body or donated for use in an individual other than the source donor, still following the concept of compatibility. Homologous PRP's usage is relatively less common and highly specific. Homologous PRP is selected for patients whose conditions align with the transplant compatibility and when allogenic and autologous options are less suitable.

Application: Extensive use of PRP treatments in orthopedic applications

Platelet rich plasma is extensively used in cosmetic surgery to promote skin rejuvenation and healing. The concentration of growth factors in platelet rich plasma can stimulate collagen production and be used for procedures such as facelifts, acne scars, and hair loss treatment. In general surgery, PRP can improve wound healing, manage incisions after surgery, and reduce the risk of infections. The need-based preference in general surgery is impacted by the potential for reduced recovery times and enhanced healing capabilities. PRP in neurosurgery finds its use in procedures involving the spine and nerve tissues, which may help reduce inflammation and facilitate recovery. The critical nature of neurosurgical procedures and the paramount importance of quick and effective healing, with minimal scarring or fibrosis, creates the need for PRP treatments. PRP is widely used in orthopedic surgery, particularly in treating tendon injuries, acute ligament, and muscle injuries, as well as for joint arthroplasty. The corresponding rise in musculoskeletal disorders among the aging population influences the need for PRP in orthopedic treatments.

Regional Insights

The platelet rich plasma market in the Americas is rapidly developing owing to a high emphasis on advancing medical procedures and sports medicine, an aging population seeking regenerative treatments for musculoskeletal conditions, and a high concentration of athletes looking for rapid recovery solutions. Customer purchasing behavior in the Americas favors innovative and minimally invasive therapies. The European Union (EU) presents a unified regulatory landscape for PRP therapies, with increasing research activity. The need for PRP treatment is fueled by a robust healthcare infrastructure and customers' preference for high-quality, regulated treatments. The Middle East has a burgeoning market for cosmetic treatments, including PRP therapies, supported by affluent consumers seeking high-end medical services. In contrast, the African PRP market is more nascent, driven primarily by gradually improving healthcare facilities and the increasing accessibility of treatments. Asia-Pacific is rapidly emerging as a significant PRP product market characterized by its large population and developing healthcare sectors. The emerging economies have shown a considerable increase in the adoption of PRP therapies, driven by rising disposable incomes and increasing medical tourism. Across the Asia Pacific, customer purchasing patterns are evolving, shifting towards valuing advanced treatments and a willingness to invest in health and wellness.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Platelet Rich Plasma Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Platelet Rich Plasma Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Platelet Rich Plasma Market, highlighting leading vendors and their innovative profiles. These include APEX Biologix, Arthrex, Inc., Cascade Medical Wellness & Aesthetics, Celling Biosciences, Inc., Crown Laboratories, Inc., Dr PRP USA LLC, EmCyte Corporation, Estar Technologies Ltd., Exactech, Inc., Factor Medical Inc., Fisher Scientific Company L.L.C., Integrity PRP, Isto Biologics, Johnson & Johnson Services, Inc., Juventix Regenerative Medical, LLC, MDBiologix, PRP Concepts, Inc., Regen Lab SA, ROCKY MOUNTAIN BIOLOGICALS, Sarstedt AG & Co. KG, Stryker Corporation, Terumo BCT, Inc., Terumo Corporation, ThermoGenesis Holdings, Inc., Ycellbio Medical Co., Ltd., and Zimmer Biomet Holdings, Inc..

Market Segmentation & Coverage

This research report categorizes the Platelet Rich Plasma Market to forecast the revenues and analyze trends in each of the following sub-markets:

Source Type
- Allogenic
- Autologous
- Homologous

Application
- Cosmetic Surgery
- General Surgery
- Neurosurgery
- Orthopedic Surgery

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Platelet Rich Plasma Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Platelet Rich Plasma Market?

3. What are the technology trends and regulatory frameworks in the Platelet Rich Plasma Market?

4. What is the market share of the leading vendors in the Platelet Rich Plasma Market?

5. Which modes and strategic moves are suitable for entering the Platelet Rich Plasma Market?

Product Code: MRR-035AB9C0DA84

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing Incidences of Sports-Related Injuries Globally
  - 5.1.1.2. Potential Application in the Treatment of Musculoskeletal Conditions and Orthopedic Disorders
  - 5.1.1.3. Increasing Use in Cosmetic Surgery and for Natural Healing Process
- 5.1.2. Restraints
  - 5.1.2.1. Uncertainty on Therapeutic Efficacy of Platelet Rich Plasma
- 5.1.3. Opportunities
  - 5.1.3.1. Emerging Application in Regenerative Medicine
  - 5.1.3.2. Ongoing Research and Development Activities on Platelet-Rich Plasma Derived Bioactive Molecules
- 5.1.4. Challenges
  - 5.1.4.1. Limited Availability of Clinical Trials and Reimbursement Policies of Platelet-rich Plasma Products
5.2. Market Segmentation Analysis
- 5.2.1. Source Type: Preference for Autologous PRP due to its safety profile
- 5.2.2. Application: Extensive use of PRP treatments in orthopedic applications
5.3. Market Trend Analysis
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
5.9. Client Customization

6. Platelet Rich Plasma Market, by Source Type

6.1. Introduction
6.2. Allogenic
6.3. Autologous
6.4. Homologous

7. Platelet Rich Plasma Market, by Application

7.1. Introduction
7.2. Cosmetic Surgery
7.3. General Surgery
7.4. Neurosurgery
7.5. Orthopedic Surgery

8. Americas Platelet Rich Plasma Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Platelet Rich Plasma Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Platelet Rich Plasma Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
- 11.3.1. Hairline International Launches Sonicated PRP- a cutting edge Hair Regeneration Therapy
- 11.3.2. Royal Biologics Announces U.S. Commercial Launch of BIOINCYTE PRFM

12. Competitive Portfolio

12.1. Key Company Profiles
12.2. Key Product Portfolio